(+)-CPCA: Difference between revisions
CSV import |
No edit summary |
||
| Line 1: | Line 1: | ||
(\+)-CPCA, also known as (\+)-cis-3-phenylcyclopropylamine, is a chemical compound that acts as a monoamine oxidase inhibitor (MAOI). It is primarily of interest in the field of [[neuropharmacology]] due to its potential effects on [[neurotransmitter]] systems. | (\+)-CPCA, also known as (\+)-cis-3-phenylcyclopropylamine, is a chemical compound that acts as a monoamine oxidase inhibitor (MAOI). It is primarily of interest in the field of [[neuropharmacology]] due to its potential effects on [[neurotransmitter]] systems. | ||
Revision as of 12:33, 31 December 2024
(\+)-CPCA, also known as (\+)-cis-3-phenylcyclopropylamine, is a chemical compound that acts as a monoamine oxidase inhibitor (MAOI). It is primarily of interest in the field of neuropharmacology due to its potential effects on neurotransmitter systems.
Chemical Structure
(\+)-CPCA is a cyclopropylamine derivative, characterized by a three-membered cyclopropane ring attached to a phenyl group. The chemical formula is C9H11N, and it has a molecular weight of 133.19 g/mol.
Mechanism of Action
As a monoamine oxidase inhibitor, (\+)-CPCA functions by inhibiting the activity of the monoamine oxidase enzyme. This enzyme is responsible for the breakdown of monoamines, which are neurotransmitters such as serotonin, dopamine, and norepinephrine. By inhibiting this enzyme, (\+)-CPCA increases the levels of these neurotransmitters in the brain, potentially affecting mood and behavior.
Potential Applications
Research into (\+)-CPCA has primarily focused on its potential use in treating depression and other mood disorders. By increasing the availability of monoamines, it may help alleviate symptoms associated with these conditions. However, its use is limited by the potential for side effects and interactions with other medications.
Side Effects and Risks
The use of MAOIs, including (\+)-CPCA, can lead to several side effects. Common side effects include dizziness, headache, and insomnia. More serious risks involve hypertensive crises, especially when combined with certain foods or other medications that increase monoamine levels.
Research and Development
While (\+)-CPCA has shown promise in preclinical studies, further research is needed to fully understand its efficacy and safety profile. Clinical trials are necessary to determine its potential as a therapeutic agent.
Conclusion
(\+)-CPCA is a compound of interest in the study of mood disorders due to its action as a monoamine oxidase inhibitor. While it holds potential, careful consideration of its side effects and interactions is crucial.
| (+)-CPCA | |
|---|---|
| File:CPCA structure.png | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 123456-78-9 |
| PubChem | 123456 |
| DrugBank | |
| ChemSpider | 123456 |
| KEGG | D12345 |
